On March 30, 2021 at 4:00 pm ET, join Jason Luke, MD and other leading experts in cancer immunotherapy as they discuss the latest and most exciting clinical updates emerging from The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020).
This FREE, CME-, CNE-, CPE- and MOC- certified webinar is a chance for clinical oncologists, registered nurses, nurse practitioners, advanced practice registered nurses, pharmacists, physician assistants, emergency physicians, allied health professionals, other patient care providers, students, and patient advocates, to learn about key clinical implications from select SITC 2020 presentations.
This live webinar will also feature a dedicated question and answer session to address your questions about clinical applications of cancer immunotherapy. Don't miss this opportunity to continue learning about the expanding cancer immunotherapy field!
REGISTER NOW
Featured presentations:
- Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) – Presenter: Karl Lewis, MD
- First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumorso – Presenter: Ignacio Melero, MD, PhD
- Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results – Presenter: Diwakar Davar, MD
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce – Presenter: Hussein Tawbi, MD, PhD
Webinar Faculty:
- Moderator: Jason Luke, MD – University of Pittsburgh Medical Center
- Presenters:
- Diwakar Davar, MD – University of Pittsburgh Medical Center
- Karl Lewis, MD – University of Colorado
- Ignacio Melero, MD, PhD – Fundación para la Investigación Médica Aplicada
- Hussein Tawbi, MD, PhD – MD Anderson Cancer Center
Webinar Agenda:
- 4-4:05 p.m. ET Overview: welcome and introductions
- 4:05-4:45 p.m. ET Presentation and discussion of content from faculty experts
- 4:45-4:55 p.m. ET Question and answer session
- 4:55-5 p.m. ET Closing remarks
Continuing Education Credit Information:
Continuing Education Credits are available for physicians, nurses, and pharmacists. To view full accreditation information, click here.
The 2020-2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.